Development of SPR/MS protein array platform

Information

  • Research Project
  • 7238078
  • ApplicationId
    7238078
  • Core Project Number
    R33RR018475
  • Full Project Number
    4R33RR018475-02
  • Serial Number
    18475
  • FOA Number
    RFA-RR-04-05
  • Sub Project Id
  • Project Start Date
    6/1/2006 - 18 years ago
  • Project End Date
    5/31/2008 - 16 years ago
  • Program Officer Name
    MARRON, MICHAEL T.
  • Budget Start Date
    6/1/2006 - 18 years ago
  • Budget End Date
    5/31/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/9/2006 - 18 years ago

Development of SPR/MS protein array platform

DESCRIPTION: State the application's broad, long-term objectives and specific aims, making reference to the health relatedness of the project. Describe concisely the research design and methods for achieving these goals. Avoid summaries of past accomplishments and the use of the first person. This abstract is meant to serve as a succinct and accurate description of the proposed work when separated from the application. If the application is funded, this description, as is, will become public information. Therefore, do not include proprietary/confidential information. DO NOT EXCEED THE SPACE PROVIDED. The main technical objective of this proposal is to develop Surface Plasmon Resonance Mass Spectrometry (SPR/MS) protein array platform that utilizes Surface Plasmon Resonance (SPR) and MALDI-TOF mass spectrometry for detection of proteins and delineation of protein-protein interactions. In the first feasibility/pilot phase, we will examine the protein arraying to an SPR-active surface, affinity retrieval of proteins on the array surface, and MALDI-TOF MS readout of the protein interactions. Functionally-active protein array will be created via spotting (arraying) and immobilization of antibodies and proteins onto a chip surface. The protein array will then be used for affinity-retrieval of proteins from solution, after which the array will be analyzed via MALDI-TOF mass spectrometry to gauge the feasibility of the MS readout of the affinity-captured proteins from the spots on the protein array. Upon the successful completion of these tasks, we will move into the second, expanded development phase, where high-resolution SPR detection will be incorporated and the integrated SPR/MS protein array platform will be used for detection of proteins and protein-protein interactions from biological fluids. A high resolution SPR array instrument will be employed to show the feasibility of quantification of the protein interactions (from individual spots) on the array. The interface between the components of the SPR/MS protein array platform, and the experiment controls and variables, will be further developed and optimized. If needed, a higher-performance microarrayer will be incorporated, and the performance of the SPR/MS protein array platform in detection of proteins and protein-protein interactions from biological fluids such as plasma and urine will be evaluated. The final result of this developmental research will be a protein chip platform and methods that can be employed into various lines of proteomics research, including high-throughput biomarker analysis, protein-protein interactions, population screening efforts, therapeutic monitoring of proteins, exploration of disease mechanism structures, and diagnostic assays development. Ultimately, the SPR/MS protein array platform could enable rapid, parallel, and high-throughput screening of protein biomarkers, using samples obtained through minimally invasive sample collection methods, propagating the screening efforts into the clinical and diagnostic laboratories. PERFORMANCE SITE(S) (organization, city, state) Intrinsic Bioprobes Inc., Tempe, AZ KEY PERSONNEL. See instructions. Use continuation pages as neededto provide the required information in the format shown below. Start with Principal Investigator. List all other key personnel in alphabetical order, last name first. Name Organization Role on Project Nedelkov, Dobrin Intrinsic Bioprobes Inc. PI Nelson, Randall W. Intrinsic Bioprobes Inc. Co-Pi Disclosure Permission Statement. Applicable to SBIR/STTR Only. Seeinstructions. 53 Yes l~l No PHS 398 (Rev. 05/01) Page_2 Form Page 2 Principal Investigator/Program Director (Last, first, middle): NedelkoV, Dobrin The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page. RESEARCH GRANT

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R33
  • Administering IC
    RR
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    505339
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:505339\
  • Funding Mechanism
  • Study Section
    ZRR1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INTRINSIC BIOPROBES, INC.
  • Organization Department
  • Organization DUNS
    965127038
  • Organization City
    TEMPE
  • Organization State
    AZ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    85284
  • Organization District
    UNITED STATES